Avita Medical's FY23 results were in line with guidance, notes Morgans, and management confirmed 2024 revenue growth of around 63%.

The company also announced profitability will be achieved by the 3Q of 2025, a goal the broker believes is achievable, with the key trigger being approval for Recell Go, due on May 31.

The analysts leave the $6.40 target unchanged and suggest post-result share price weakness is a great buying opportunity. Add.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $6.40.Current Price is $4.78. Difference: $1.62 - (brackets indicate current price is over target). If AVH meets the Morgans target it will return approximately 25% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2024 Acquisdata Pty Ltd., source FN Arena